Release Summary

Inotek Pharmaceuticals today announced the completion of the active recruitment phase of the Phase 2 fixed-dose combination (FDC) trial of trabodenoson and latanoprost for the treatment of glaucoma.

Inotek Pharmaceuticals Corporation